1848-90-4

Usage

Uses

Used in Pharmaceutical Industry:
Pimozide is utilized as an antipsychotic agent for the treatment of chronic schizophrenia and other psychotic disorders. Its mechanism of action involves the blockade of D2 dopamine receptors, which helps in reducing the intensity of psychotic symptoms.
Used in Off-Label Treatments:
Although not its primary indication, pimozide is also used off-label to manage conditions such as Tourette syndrome and other tic disorders, where its dopamine receptor blocking properties can be beneficial in alleviating the associated symptoms.
Used in Oral Tablet Form:
Pimozide is typically available in oral tablet form, making it a convenient mode of administration for patients under medical supervision. It is crucial that pimozide is used only under the guidance of a healthcare professional to monitor for potential side effects and to manage drug interactions effectively.

InChI:InChI=1/C10H10N2O3/c1-11-7-4-2-3-5-8(7)12(10(11)15)6-9(13)14/h2-5H,6H2,1H3,(H,13,14)

Upstream product

• 910322-52-0 (3-methyl-2-oxo-2,3-dihydrobenzoimidazol-1-yl)acetic acid benzyl ester 

Relevant academic research and scientific papers

2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS

The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.

Ramoplanin derivatives possessing antibacterial activity

Novel ramoplanin derivatives are disclosed. These ramoplanin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against gram positive bacteria, they are useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists

A rapid analogue approach to identification of spirohydantoin-based CGRP antagonists provided novel, low molecular weight leads. Modification of these leads afforded a series of nanomolar benzimidazolinone-based CGRP receptor antagonists. The oral bioavai